In a report released on February 2, Robyn Karnauskas from Truist Financial reiterated a Buy rating on Arcus Biosciences (RCUS – Research Report), with a price target of $50.00. The company’s shares closed yesterday at $21.07. According to TipRanks, Karnauskas is a 5-star analyst with an average return of 9.0% and a 53.38% success rate. Karnauskas covers the Healthcare sector, focusing on stocks such as Biogen, BioMarin Pharmaceutical, and Eli Lilly & Co. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arcus Biosciences with a $43.67 average price target, which is a 107.26% upside from current levels. In a report released on February 2, Mizuho Securities also maintained a Buy rating on the stock with a $51.00 price target. See the top stocks recommended by analysts >> RCUS market cap is currently $1.49B and has a P/E ratio of 22.16.
		  Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RCUS in relation to earlier this year. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.  Read More on RCUS: Indices Commodities Currencies Stocks